← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Apogee Biotechnology Corporation
Hummelstown, PA
$15,624,245
Total funding
25
Grants
Funding over time
peak $1.8M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$15,424,245 · 24
FDA$200,000 · 1
By mechanism
R44$8,280,518 · 5
R43$4,414,281 · 14
R41$1,387,895 · 3
R42$1,141,551 · 1
N01$200,000 · 1
R01$200,000 · 1
Investigators at Apogee Biotechnology Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
Sphingosine Kinase Inhibitors as Anti-Retinopathy Agents$953,134
R44 · FY2007 · EY
Sphingosine Kinase Inhibitors as Anti-Retinopathy Agents$921,669
R44 · FY2008 · EY
Opaganib as a Medical Countermeasure for Gastrointestinal Acute Radiation Syndrome$882,744
R44 · FY2024 · AI
Sphingosine Kinase Inhibitors as Anti-IBD Agents$874,563
R44 · FY2007 · DK
Opaganib as a Medical Countermeasure for Gastrointestinal Acute Radiation Syndrome$852,174
R44 · FY2023 · AI
Sphingosine Kinase Inhibitors as Anti-IBD Agents$819,846
R44 · FY2006 · DK
Clinical Trial of ABC294640 in Patients with Refractory Multiple Myeloma$666,666
R44 · FY2015 · CA
Clinical Trial of ABC294640 in Patients with Refractory Multiple Myeloma$659,861
R44 · FY2016 · CA
Clinical Trial of ABC294640 in Patients with Refractory Multiple Myeloma$653,219
R44 · FY2017 · CA
Sphingosine Kinase Inhibitors as Anti-Arthritis Agents$515,195
R44 · FY2009 · AR
An Early-Phase Clinical Trial Evaluating ABC294640 in Patients with Refractory/Re$509,024
R42 · FY2014 · CA
An Early-Phase Clinical Trial Evaluating ABC294640 in Patients with Refractory/Re$499,411
R42 · FY2015 · CA
Sphingosine Kinase Inhibitors as Anti-Arthritis Agents$481,447
R44 · FY2008 · AR
Inhibitors of Human Pal mitoyl Acyltransferase$348,905
R43 · FY2004 · CA
Treatment of Inflammatory Bowel Disease with Ceramidase Inhibitors$316,916
R43 · FY2012 · DK
Lipid Metabolism and KSHV-associated Lymphoma Pathogenesis$300,000
R41 · FY2011 · AI
Lipid Metabolism and KSHV-associated Lymphoma Pathogenesis$300,000
R41 · FY2010 · AI
Mitigation of Radiation-Induced Pulmonary Fibrosis by a Sphingosine Kinase Inhibi$300,000
R43 · FY2013 · AI
Inhibitors of Human Pal mitoyl Acyltransferase$298,556
R43 · FY2005 · CA
Mitigation of Radiation-Induced Pulmonary Fibrosis by a Sphingosine Kinase Inhibi$293,448
R43 · FY2014 · AI